At a 2026 oncology conference in Tucson, physicians confronted a recurring truth in cancer medicine: that progress rarely arrives as a single breakthrough, but as a series of incremental reckonings with complexity. Across bladder, prostate, and kidney cancers, new combinations of immunotherapy and targeted agents are improving survival — yet each advance carries its own burden of judgment, demanding that clinicians weigh not just efficacy, but timing, toxicity, and the readiness of practice to absorb change. The science is moving faster than the systems built to deliver it, and the distance be